MX362610B - Usos de bremelanotida en terapia para la disfunción sexual femenina. - Google Patents
Usos de bremelanotida en terapia para la disfunción sexual femenina.Info
- Publication number
- MX362610B MX362610B MX2015005486A MX2015005486A MX362610B MX 362610 B MX362610 B MX 362610B MX 2015005486 A MX2015005486 A MX 2015005486A MX 2015005486 A MX2015005486 A MX 2015005486A MX 362610 B MX362610 B MX 362610B
- Authority
- MX
- Mexico
- Prior art keywords
- bremelanotide
- sexual dysfunction
- female sexual
- therapy
- women
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
Abstract
La presente invención se refiere a una composición que comprende bremelanotida o una sal farmacéuticamente aceptable de la misma para usarse en el tratamiento de la disfunción sexual femenina en una paciente diagnosticada con disfunción sexual femenina y anticipando la actividad sexual, en donde la composición está adaptada para ser administrable mediante inyección subcutánea, la composición que comprende bremelanotida o una sal farmacéuticamente aceptable de bremelanotida en u na cantidad suficiente para dar como resultado una concentración plasmática máxima de bremelanotida dentro de los 60 minutos posteriores a la administración de bremelanotida en la paciente femenina de nomás de 120 ng/ml , en donde entre 1.00 mg y 1.75 mg de bremelanotida o una sal farmacéuticamente aceptable de bremelanotida está adaptada para ser administrable preferiblemente entre 1.25 y 1.75 mg, para tratar así la disfunción sexual femenina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261722511P | 2012-11-05 | 2012-11-05 | |
| US201361770535P | 2013-02-28 | 2013-02-28 | |
| PCT/US2013/068386 WO2014071339A2 (en) | 2012-11-05 | 2013-11-05 | Uses of bremelanotide in therapy for female sexual dysfunction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015005486A MX2015005486A (es) | 2015-11-13 |
| MX362610B true MX362610B (es) | 2019-01-28 |
Family
ID=50628268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015005486A MX362610B (es) | 2012-11-05 | 2013-11-05 | Usos de bremelanotida en terapia para la disfunción sexual femenina. |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US9352013B2 (es) |
| EP (1) | EP2916856B2 (es) |
| JP (1) | JP6567971B2 (es) |
| KR (1) | KR102253526B1 (es) |
| CN (2) | CN104755094A (es) |
| AU (1) | AU2013337341B2 (es) |
| BR (1) | BR112015009936A8 (es) |
| CA (1) | CA2890081A1 (es) |
| DK (1) | DK2916856T4 (es) |
| EA (1) | EA032959B9 (es) |
| ES (1) | ES2701444T5 (es) |
| FI (1) | FI2916856T4 (es) |
| GE (1) | GEP20196947B (es) |
| HK (1) | HK1211227A1 (es) |
| IL (1) | IL238276B (es) |
| MX (1) | MX362610B (es) |
| MY (1) | MY179755A (es) |
| NZ (1) | NZ707246A (es) |
| PH (1) | PH12015500915A1 (es) |
| PL (1) | PL2916856T5 (es) |
| SG (1) | SG11201502949QA (es) |
| UA (1) | UA118656C2 (es) |
| WO (1) | WO2014071339A2 (es) |
| ZA (1) | ZA201503128B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11590209B2 (en) * | 2020-01-21 | 2023-02-28 | Palatin Technologies, Inc. | Use of bremelanotide in patients with controlled hypertension |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7235625B2 (en) * | 1999-06-29 | 2007-06-26 | Palatin Technologies, Inc. | Multiple agent therapy for sexual dysfunction |
| US6579968B1 (en) * | 1999-06-29 | 2003-06-17 | Palatin Technologies, Inc. | Compositions and methods for treatment of sexual dysfunction |
| US7176279B2 (en) | 2000-06-28 | 2007-02-13 | Palatin Technologies, Inc. | Cyclic peptide compositions and methods for treatment of sexual dysfunction |
| US7022674B2 (en) | 1999-12-16 | 2006-04-04 | Eli Lilly And Company | Polypeptide compositions with improved stability |
| DE60112440T2 (de) * | 2000-05-31 | 2006-04-20 | Novo Nordisk A/S | Wegwerfbare zweispitzige injektionsnadel |
| CA2453515A1 (en) | 2001-07-11 | 2003-01-23 | Palatin Technologies, Inc. | Linear and cyclic melanocortin receptor-specific peptides |
| BRPI0518961A2 (pt) * | 2004-12-09 | 2008-12-16 | West Pharm Serv Inc | acoplamento para dispositivo de injeÇço automÁtica |
| WO2009120656A1 (en) * | 2008-03-24 | 2009-10-01 | Palatin Technologies, Inc. | Pharmaceutical for ocular indications |
| EA018630B1 (ru) * | 2008-06-09 | 2013-09-30 | Палатин Текнолоджиз, Инк. | Специфичные к меланокортиновым рецепторам пептиды для лечения сексуальной дисфункции |
| WO2011060352A1 (en) * | 2009-11-16 | 2011-05-19 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of melanocortin receptor ligands |
| CN103118737B (zh) * | 2010-04-21 | 2015-05-20 | 艾伯维生物技术有限公司 | 用于治疗药剂的受控输送的可佩戴自动注射装置 |
-
2013
- 2013-11-05 BR BR112015009936A patent/BR112015009936A8/pt not_active Application Discontinuation
- 2013-11-05 WO PCT/US2013/068386 patent/WO2014071339A2/en active Application Filing
- 2013-11-05 UA UAA201503523A patent/UA118656C2/uk unknown
- 2013-11-05 DK DK13851014.4T patent/DK2916856T4/da active
- 2013-11-05 CN CN201380056487.9A patent/CN104755094A/zh active Pending
- 2013-11-05 CA CA2890081A patent/CA2890081A1/en active Pending
- 2013-11-05 EA EA201590760A patent/EA032959B9/ru not_active IP Right Cessation
- 2013-11-05 AU AU2013337341A patent/AU2013337341B2/en active Active
- 2013-11-05 JP JP2015540853A patent/JP6567971B2/ja active Active
- 2013-11-05 SG SG11201502949QA patent/SG11201502949QA/en unknown
- 2013-11-05 FI FIEP13851014.4T patent/FI2916856T4/fi active
- 2013-11-05 CN CN202410025611.5A patent/CN117860866A/zh active Pending
- 2013-11-05 EP EP13851014.4A patent/EP2916856B2/en active Active
- 2013-11-05 ES ES13851014T patent/ES2701444T5/es active Active
- 2013-11-05 MY MYPI2015001016A patent/MY179755A/en unknown
- 2013-11-05 PL PL13851014.4T patent/PL2916856T5/pl unknown
- 2013-11-05 NZ NZ707246A patent/NZ707246A/en unknown
- 2013-11-05 GE GEAP201313826A patent/GEP20196947B/en unknown
- 2013-11-05 MX MX2015005486A patent/MX362610B/es active IP Right Grant
- 2013-11-05 KR KR1020157014777A patent/KR102253526B1/ko active IP Right Grant
-
2014
- 2014-06-24 US US14/313,258 patent/US9352013B2/en active Active
-
2015
- 2015-04-14 IL IL238276A patent/IL238276B/en active IP Right Grant
- 2015-04-23 PH PH12015500915A patent/PH12015500915A1/en unknown
- 2015-05-05 US US14/704,223 patent/US9700592B2/en active Active
- 2015-05-07 ZA ZA2015/03128A patent/ZA201503128B/en unknown
- 2015-12-08 HK HK15112118.5A patent/HK1211227A1/xx unknown
-
2017
- 2017-07-06 US US15/642,772 patent/US10286034B2/en active Active
-
2019
- 2019-03-28 US US16/368,417 patent/US20190216888A1/en not_active Abandoned
-
2020
- 2020-10-27 US US17/081,732 patent/US20210060120A1/en not_active Abandoned
-
2022
- 2022-07-14 US US17/864,486 patent/US20220362328A1/en not_active Abandoned
-
2024
- 2024-06-13 US US18/742,358 patent/US20240335502A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018001659A (es) | Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer. | |
| NZ732507A (en) | Improved compositions for treating muscular dystrophy | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| MX2014010590A (es) | Terapia de combinacion para trastornos proliferativos. | |
| PH12018502134A1 (en) | Methods of treating pediatric cancers | |
| MX2024010140A (es) | Nuevos metodos. | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| WO2013188210A3 (en) | Treatment of side effects associated with parkinson's disease treatments | |
| MX2022000143A (es) | Metodos novedosos. | |
| MX2021014523A (es) | Metodos para tratar colangiocarcinoma. | |
| MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
| PH12021551235A1 (en) | Elacestrant in combination with abemaciclib in women with breast cancer | |
| UA115250C2 (uk) | Фармацевтичні комбінації | |
| PH12015500915A1 (en) | Bremelanotide therapy for female sexual dysfunction | |
| MX2012005497A (es) | Tivozanib y temsirolimus en combinacion. | |
| MX349767B (es) | Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil) -naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular. | |
| NZ599227A (en) | Therapeutic agent for chronic pain | |
| MX2018001528A (es) | Composicion farmaceutica que comprende sumatriptan para tratamiento de migraña. | |
| TN2013000336A1 (en) | 5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy. | |
| ZA202102913B (en) | Dosage regime |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |